key: cord-0906647-n88c87y4 authors: Mendes-Correa, M. C.; Vilas-Boas, L. S. S.; Bierrenbach, A. L.; Vincente de Paula, A.; Tozetto-Mendoza, T. R.; Leal, F. E.; Freire, W.; Paiao, H. G. O.; Ferraz, A. d. B. C.; Witkin, S. S. title: Individuals who were mildly symptomatic following infection with SARS-CoV-2 B.1.1.28 have neutralizing antibodies to the P.1 variant. date: 2021-05-17 journal: nan DOI: 10.1101/2021.05.11.21256908 sha: 433e62d8d3d80ffac0f1713c3682aa85a3df3189 doc_id: 906647 cord_uid: n88c87y4 Abstract Objectives: To evaluate if antibodies induced by infection with SARS-CoV-2 B.1.128 neutralize the P.1 variant. Methods: Convalescent sera from 60 individuals who had mild symptoms that did not require hospitalization following a documented SARS-CoV-2 infection (B.1.128 lineage) were assayed for neutralizing antibody titer against their original strain and against the SARS-CoV-2 P.1 variant. Results: Fifty-six (94%) and 50 (84 %) sera were positive for neutralizing antibodies against the ancestral and P.1 strains, respectively, and remained positive throughout the 6-week study period. Neutralization titers were consistently higher against the ancestral strain (p[≤] 0.001), but in the majority of patients (57.8%) differences did not differ by more than a single dilution. Conclusions: Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals. Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, one of the major concerns has been the duration of immune protection and its specificity following the initial infection. The long term clinical and immunological consequences of anti-viral antibody production against the infecting strain remain unclear and correlations between antibody levels and protection against re-infection by SARS-CoV-2 variants remain under-reported 1,2 . Neutralizing antibodies are antibodies that react with surface components of SARS-CoV-2, specifically the spike protein, and prevent the virus from interacting with specific receptors on target cells and thereby initiating a productive infection 1, 3 . Measuring and comparing the neutralization capacity of antibodies in sera from convalescent individuals previously infected with SARS-CoV-2 strains circulating at the beginning of the pandemic with genetic variant strains present at late pandemic stages will provide much needed information regarding the occurrence of cross-immunity between different viral strains. Beginning in November 2020, a novel SARS-CoV-2 variant, lineage P.1, was identified in Manaus, Brazil 4 . Genome sequencing demonstrated that this variant is characterized by 17 mutations, including three in the gene coding for the spike protein (K417T, E484K and N501Y). These mutations result in antigenic changes in the spike protein and could impair the efficacy of neutralizing antibodies that were generated against a previous SARS-CoV-2 strain 5 . The P.1 SARS-CoV-2 variant has spread throughout Brazil and has become prominent in perpetuating and expanding the pandemic in this country. The aim of the present study was to evaluate if neutralizing antibody responses induced by infection with the SARS-CoV-2 virus that was dominant at the beginning of the pandemic remained effective when tested against the P.1 lineage. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. To isolate SARS-CoV-2 we used Vero cells (ATCC® CCL-81™). Cells were seeded in a 25 cm 2 cell culture flask (polystyrene sterile, non-pyrogenic flask,12.5 cm 2 , 25mL, Biofil®, China) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 17, 2021. ; https://doi.org/10.1101/2021.05.11.21256908 doi: medRxiv preprint in a concentration of 5 ×10 5 cells/mL in 3.0 mL Dulbecco Minimal Essential Medium (DMEM) supplemented with 5% heat-inactivated fetal bovine serum (FBS) (Vitrocell Embriolife, Campinas, Brazil) and incubated overnight at 37°C. The next day, the supernatant was discarded, and 0.5 mL of a homogenized nasopharyngeal (NP) swab specimen was added into the culture flask. After 1 h of incubation (adsorption), we supplemented the volume with 3.0 mL DMEM containing 2.5% FBS and 1% penicillin-streptomycin and inoculated the cultures in a humidified 37°C incubator in an atmosphere of 5% CO 2. We observed for the presence of cytopathic effects (CPE) daily for 3-5 days. The supernatant was collected, and virus replication was confirmed through CPE and by RT-PCR. The viral titer was expressed in TCID 50 /mL and calculated using the Spearman & Kärber All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 17, 2021. ; https://doi.org/10.1101/2021.05.11.21256908 doi: medRxiv preprint For each reaction we used as a positive control diluted virus in DMEM with 2.5% FBS and as a negative control only DMEM with 2.5% FBS. In addition, a serum control was a serum specimen taken from a patient with a SARS-CoV-2 infection in São Paulo with a known VTN titer. The antibody titer was calculated as the highest dilution where CPE was completely inhibited. Titers >1:20 were reported as positive. Virus isolation and VNT were performed in a Biosafety Level 3 laboratory. We investigated whether convalescent individuals have similar serum virus neutralization titers against isolates of SARS-CoV-2 lineage "P.1" as compared to the ancestral lineage. The equality of matched pairs of observations was tested using the Wilcoxon matchedpairs signed-rank test. We also calculated the paired differences in dilution titers and subsequently categorized these differences into "≤ -2", "in between -1 and 1" and "≥ 2". Database management and statistical analysis were performed using the Stata-15 software (Statacorp, College Station, Texas, USA). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 17, 2021. ; https://doi.org/10.1101/2021.05.11.21256908 doi: medRxiv preprint Demographics and clinical characteristics of the study population are presented in Table 1 Supplementary. The majority (58.3%) were female and 46.6% were <40 years old. All had mild or moderate disease with symptoms lasting a median of 3 days; none required hospitalization. Table 1 . Median values were consistently higher against the ancestral strain than against the P1 lineage. All differences reached statistical significance, except for week one. When comparing the neutralization titers against the ancestral strain and P.1, we observed that this difference was not more than a single dilution in 57.8%, not more than two dilutions in 37.6% and > 2 dilutions in only 4.6% of the sera ( Table 2 Supplementary material). The differences remained fairly constant over the time course of the study (Fig. 2 Supplementary material). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 17, 2021. ; https://doi.org/10.1101/2021.05.11.21256908 doi: medRxiv preprint The great majority of patients infected with one SARS-CoV-2 strain (B.1.1.28 lineage) developed neutralizing antibodies that were also effective in vitro, although at a slightly reduced titer, against the P.1 variant, without having a prior exposure to this strain. It is likely that the small difference in neutralization titers would not diminish the ability to effectively prevent or minimize infection following exposure to the P.1 variant. Thus, previous infections with the ancestral strains will apparently provide a sufficient degree of protection from the P.1. variant in the majority of previously infected individuals. This protection may also extend to other components of the immune response, such as long-lived memory T cells 13 . It has already been postulated that even when neutralizing antibody levels have dropped below a detectable threshold, immune memory could lead to induction of an anamnestic antibody response following re-exposure to the same or different strains of the virus, and this is likely to be protective against severe disease 1 .The reason(s) for the difference in neutralization antibody titers against the ancestral lineage that produced the infection and the P.1variant remain to be determined. It is likely that they reflect variations in the conformation of the spike protein that influences the efficacy of antibody binding 5, 14 . This possibility has been evaluated in only a few studies 5 and the mechanism remains unresolved. It is important to acknowledge limitations of our study. First, our cohort included a relatively small number of patients, all of whom recovered from mild or moderate episodes of COVID-19. It would be of interest to expand the study to determine if individuals with more severe disease differed in the occurrence or titer of antibodies cross-reactive to P.1. Secondly, our study only assessed neutralizing antibody titers for the first six weeks after initial infection. The length of time that the neutralizing antibody titers to the initiating strain and to the P.1 variant are maintained remains to be determined. Extending this study to later time points would be valuable to gain this additional information. Data on humoral immunity to other human coronaviruses have indicated that antibody levels wane over time 2 . A few studies have assessed antibody titers to MERS CoV and SARS CoV in the months and years following primary infection. Although limited in size these studies indicated that total binding antibodies and neutralizing antibodies progressively decreased such that by 2-3 years all infected All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 17, 2021. ; https://doi.org/10.1101/2021.05.11.21256908 doi: medRxiv preprint individuals had minimal detectable antibody responses. There are reports of reinfection with homologous coronaviruses after as little as 80 days 2 . Thirdly, we did not measure other components of the immune response, such as cellmediated immunity, which would further contribute to viral neutralization in vivo. It is likely that large prospective epidemiologic studies will be required to establish the role of neutralizing antibodies in preventing infection, or minimizing their consequences, by SARS-CoV-2 variants in previously exposed individuals. This will also most likely vary depending on the extent of changes in spike protein antigenicity between the infecting strain and the specific variant being analyzed. In conclusion, our data provides the encouraging information that a previous SARS-CoV-2 infection likely provides a substantial degree of protection against the P.1 variant, even in most individuals with a relatively mild infection. The study was approved by the local ethics committee (CONEP, protocol No. CAAE: 30419320.7.0000.0068, dated April 18, 2020) and all subjects provided informed written consent. Author contributions. All authors made a significant contribution at different stages of the study and contributed to data interpretation. MCMC and SSW wrote the first draft of the paper. ALB was responsible for the statistical analysis. All authors participated in writing subsequent drafts. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 120 (40-320) Signed-rank tests were used to compare differences in the matched pairs. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 17, 2021. ; https://doi.org/10.1101/2021.05.11.21256908 doi: medRxiv preprint Figure 1 . Positivity of neutralization titers against isolates "ancestral" lineage compared to those against the "P.1" lineage, by week since onset of symptoms. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 17, 2021. ; https://doi.org/10.1101/2021.05.11.21256908 doi: medRxiv preprint Table 2 Supplementary material. Paired dilution differences of neutralization titers against isolates of SARS-CoV-2 "ancestral" lineage compared to those against the "P.1" lineage, by weeks since onset of symptoms. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 17, 2021. ; https://doi.org/10.1101/2021.05.11.21256908 doi: medRxiv preprint Figure 2 Supplementary material. Differences in neutralization titers against the SARS-CoV-2 ancestral strain and the "P.1" lineage over the six-week study period. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 17, 2021. ; https://doi.org/10.1101/2021.05.11.21256908 doi: medRxiv preprint Neutralizing antibody titres in SARS-CoV-2 infections The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection SARS-CoV-2 antibody testing-questions to be asked Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil Antibody evasion by the P.1 strain of SARS-CoV-2, 1 Virus titration -Supplementary Biofil®) containing 5 × 10 4 cells/mL Vero CCL-81 cells in DMEM. A virus preparation was 10-fold serially diluted in medium (10 -1 to 10 -12 ), the original culture medium was then removed and replaced with serial dilutions of the virus in sextuplicate wells and incubated at 37°C. Observations were performed daily using an inverted light microscope (Nikon 45178, Japan) to verify the presence of CPE over a 72 h period Germany) dissolved in sodium acetateacid acetic. The viral titer was expressed in TCID 50 /mL and calculated using the Spearman & Kärber algorithm Virus isolation and quantitation We thank the staff from Laboratorio de Investigacao Medica em Virologia (LIM52)-Instituto de Medicina Tropical de Sao Paulo for general laboratory support.We also thank Prof.Ester Sabino from Instituto de Medicina Tropical de São Paulo, for providing the isolates from nasopharyngeal specimens from Manaus City, Brazil.All authors approved the final version of the manuscript. The authors declare that they have no known competing financial interests. ≥ 61, n (%) 9 (15%) Hospitalization, n (%) 0 Duration of symptoms (days), median (range) 3 (1-10)